OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market

OneMedNet retains direct control of data sourcing, curation and de-identification under its channel distribution strategy.

Rhea-AI Summary

OneMedNet (ONMD) signed its 12th channel partner agreement, adding a global pharmaceutical intelligence and data provider to its distribution network.

The unnamed partner will distribute OneMedNet’s U.S.-sourced, de-identified clinical data to its established pharmaceutical customer base worldwide. The agreement extends distribution of real-world data, or information drawn from clinical care. OneMedNet said the partnership expands its pharmaceutical-market reach through established distribution channels.

Positive

• Minor point12th channel agreement adds distribution to the partner’s established pharmaceutical customer base worldwide.

Negative

• None.

Key Figures

Channel partner count: 12th channel partner agreement Global Real-World Data market: $2.7 billion Global Real-World Data market: $7.1 billion

Channel partner count

12th channel partner agreement

OneMedNet's announced agreement

Global Real-World Data market

$2.7 billion

2026 estimate

Global Real-World Data market

$7.1 billion

Projected by 2033

Historical Context

2 past events · Latest: Oct 07

2 events

1. Oct 07

   Channel partnership

   24h Move

   -1.2%

   Signed its 11th channel partner agreement with Mediplexus for Korea distribution.

2. Sep 30

   Channel partnership

   24h Move

   +11.1%

   Signed a seven-figure, multiyear data agreement with its tenth channel partner.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

real-world data, de-identified, multimodal

3 terms

real-world data medical

"distribution of OneMedNet’s first-party, direct-from-source multimodal Real-World Data"

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

de-identified technical

"U.S.-sourced, de-identified clinical data"

Data labeled as de-identified has had names and other direct personal details removed or masked so individual people cannot be readily recognized; think of it like blurring faces and removing name tags from a photo. For investors, de-identification matters because it reduces legal and privacy risk, can change how valuable or usable the data is for research or product development, and affects regulatory compliance and potential liabilities.

multimodal technical

"first-party, direct-from-source multimodal Real-World Data"

Multimodal describes an approach, product, or system that uses two or more different types of inputs, methods, or channels — for example combining text, images and audio in a technology product, or blending drugs, devices and therapy in medical care. For investors, multimodal solutions can broaden market reach and competitive differentiation but also add development cost, operational complexity and regulatory hurdles; think of it like a hybrid car that offers more capabilities but requires more parts and oversight.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Agreement with a leading global provider of pharmaceutical intelligence and data solutions expands distribution of OneMedNet’s first-party, direct-from-source multimodal Real-World Data; Strengthening its presence in a rapidly growing pharmaceutical data market

MINNEAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced its 12th channel partner agreement, under which a leading global provider of pharmaceutical intelligence and data solutions will distribute OneMedNet’s U.S.-sourced, de-identified clinical data to its established base of pharmaceutical customers worldwide. The agreement broadens OneMedNet’s reach into one of the fastest-growing segments of life sciences data. The global Real-World Data market is estimated at approximately US$2.7 billion in 2026 and is projected to reach US$7.1 billion by 2033, according to Coherent Market Insights¹, as pharmaceutical companies increasingly rely on Real-World Data to support drug development, regulatory submissions, and commercial decisions.

OneMedNet is witnessing data partners increasingly select its Real-World Data for the qualities pharmaceutical customers value most: first-party data sourced directly from healthcare providers rather than intermediaries or secondary markets, de-identified at the source, and delivered at regulatory-grade quality. By pairing OneMedNet’s multimodal clinical data with their own analytics and intelligence offerings, partners can support their pharmaceutical customers across clinical development, regulatory submissions, market access, and medical AI.

This agreement marks OneMedNet’s 12th channel partnership, reflecting a deliberate strategy to extend the Company’s commercial reach through established distribution channels while maintaining direct control of data sourcing, curation, and de-identification.

“We believe our channel partners choose OneMedNet for the same reason end customers do: data that comes straight from the source,” said Aaron Green, President & CEO of OneMedNet. “First-party, direct-from-source data gives our partners confidence in the quality, provenance, and compliance of what they deliver to their customers. This partnership expands our reach in the pharmaceutical market.”

About OneMedNet Corporation

OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Learn more at www.onemednet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the benefits and expected scope of the channel partner agreement, our distribution strategy, and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing

Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

1. https://www.coherentmarketinsights.com/market-insight/real-world-data-rwd-market-6029
   
   

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does OneMedNet’s new pharmaceutical channel partner agreement cover?

The partner will distribute OneMedNet’s U.S.-sourced, de-identified clinical data to its established pharmaceutical customers worldwide. The agreement is OneMedNet’s 12th channel partnership; the partner is described as a global pharmaceutical intelligence and data provider but is not named.